Bradykinin induces peripheral antinociception in PGE2-induced hyperalgesia in mice

• Published in: Biochemical pharmacology 2022-04, Vol.198, p.114965-114965, Article 114965
• Main Authors: Ferreira, Renata Cristina Mendes, de Sousa Fonseca, Flávia Cristina, de Almeida, Douglas Lamounier, Freitas, Ana Cristina Nogueira, Peigneur, Steve, Romero, Thiago Roberto Lima, Amaral, Flávio Almeida, Duarte, Igor Dimitri Gama
• Format: Article
• Language: English
• Subjects: Antinociception; Bradykinin; Cannabinoid; Opioid
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2022.114965

[Display omitted] Bradykinin (BK) is an endogenous peptide involved in vascular permeability and inflammation. It has opposite effects (inducing hyperalgesia or antinociception) when administered directly in the central nervous system. The aim of this study was to evaluate whether BK may also present this dual effect when injected peripherally in a PGE2-induced nociceptive pain model, as well as to investigate the possible mechanisms of action involved in this event in mice. Male Swiss and C57BL/6 knockout mice for B1 or B2 bradykinin receptors were submitted to a mechanical paw pressure test and hyperalgesia was induced by intraplantar prostaglandin E2 (2 µg/paw) injection. Bradykinin (20, 40 and 80 ng/paw) produced dose-dependent peripheral antinociception against PGE2-induced hyperalgesia. This effect was antagonized by bradyzide (8, 16 and 32 μg/paw), naloxone (12.5, 25 and 50 μg/paw), nor-binaltorphimine (50, 100 and 200 μg/paw) and AM251 (20, 40 and 80 μg/paw). Bestatin (400 µg/paw), MAFP (0.5 µg/paw) and VDM11 (2.5 µg/paw) potentiated the antinociception of a lower 20 ng BK dose. The knockout of B1 or B2 bradykinin receptors partially abolished the antinociceptive action of BK (80 ng/paw), bremazocine (1 μg/paw) and anandamide (40 ng/paw) when compared with wild-type animals, which show complete antinociception with the same dose of each drug. The present study is the first to demonstrate BK-induced antinociception in peripheral tissues against PGE2-induced nociception in mice and the involvement of κ-opioid and CB1 cannabinoid receptors in this effect.